NephroGenex, Inc. Report issue

For profit Phase 3
Founded: Princeton NJ United States (2004)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2008
NCT00734253
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

pyridoxamine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Nephropathies (Phase 3)

Kidney Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1